SAN DIEGO — An adjunctive, first-in-class investigational prescription digital therapeutic significantly reduced monthly migraine days (MMDs) in patients with episodic migraine (EM) compared with sham results of a large study showed.

CT-132 (Click Therapeutics) is a mobile smartphone app that “targets top-down pain processing and central sensitization” using behavioral approaches and includes an eDiary tracker and short daily lessons/exercises with a decision-support tool, the investigators reported.

“I think this is very exciting as a clinician who takes cares of patients because we don’t have anything like this in our migraine armamentarium,” co-investigator Stewart J. Tepper, MD, professor of neurology at the Dartmouth Geisel School of Medicine, Hanover, New Hampshire, told Medscape Medical News.

“We know that behavioral techniques are helpful adjunctively, but large areas of the country just don’t have access to them,” added Tepper, who is also vice president of the New England Institute for Neurology and Headache, Stamford, Connecticut.

The findings were presented on April 6 in a poster presentation at the American Academy of Neurology (AAN) 2025 Annual Meeting.

Source: MEDspace